NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,010.15 mln
Float94.78 mln
Earnings Date03/04/2027
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
37.00
Transformational upside
Relative Strength
9
/ 100
Severely lagging
Debt / Equity
0.22
Very low leverage
Pre-Tax Margin
-46%
Deeply loss-making
ROE
-9.86
Negative
Business Description
Mesoblast is an Australian biotech company founded in 2004 that develops cell-based therapies to treat serious inflammatory and degenerative conditions across multiple countries. Its work centers on a specialized cell technology used to create treatments for conditions such as graft versus host disease, heart failure, inflammatory bowel disease, and chronic back pain. The company has formed partnerships with pharmaceutical firms including Tasly, JCR Pharmaceuticals, and Grünenthal to bring several of these therapies to patients around the world.
